Abstract: Immunotherapy, represented by immune checkpoint inhibitors, may lead to immune-related adverse events (irAEs) while demonstrating favorable efficacy in patients with malignant tumors. Many domestic and international guidelines or consensus have been established to assist clinicians in effectively managing the majority of irAEs. However, further exploration about irAEs is required regarding the definition and determination, temporal patterns, individual variances, utilization of hormones and immunosuppressants, correlation between irAEs and therapeutic outcomes, immune reactivation, and special populations. The identification and management of severe, refractory, and multiple irAEs necessitate additional solutions. This paper aims to clarify 10 prominent issues concerning irAEs individually and provide assistance for clinicians.